12月9日早盘，A股、港股创新药概念均表现活跃。热门ETF中，创新药ETF（159992）截至9:57涨约 1%，成交额超1.5亿元。 成分股来看，迪哲医药、恒瑞医药、泰格医药等涨幅居前；通化金马、人福医药、特宝生物等小幅领 跌。 消息面上，2025年国家医保药品目录及首版商保创新药目录在广州发布。2025年国家医保药品目录成功 新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。19种药品纳入首 版商保创新药目录。 每日经济新闻 中信建投认为，国家医保谈判成功率创新高，商保目录有望成为重要增量，政策鼓励创新药发展。与此 同时，中国创新药管线国际化竞争力持续提升，出海模式持续升级，新技术推动行业快速发展。看好相 关创新药及制药企业。 资料显示，创新药ETF（159992，场外联接A类：012781；C类：012782）紧密跟踪中证创新药产业指 数，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的整体表 现。 ...

12月9日早盘，港股通创新药板块短线企稳，创新药含量100%的港股通创新药ETF（520880）水面上方 震荡，成份股走势分化，恒瑞医药、山东新华制药股份领涨超2%，MIRXES-B跌3%，信达生物跌逾 1%。 值得关注的是，港股通创新药ETF（520880）场内延续高溢价，显示低吸资金仍活跃。昨日520880回调 1%区间，单日获超5600万元资金净申购，创近1个月来单日吸金额新高。 | 分时 多日 1分 5分 15分 30分 · | | | | | | | F9 盘前盘目 盘加 九轮 面班 工具 份 (7 2) | | | | | 港股通创新药ETF O | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.557 | | | | 520880[高版通创新的ETF] 09:46 价 0.554 图表 0.002(0.36%) 均价 0.554 版交盘 7 _ _ _ _ | | | | | | 0.554 +0.002 +0.36% | | CONDON 7 ...

Core Insights - The 2025 Innovative Drug High-Quality Development Conference will be held on December 7, 2025, in Guangzhou, where the National Healthcare Security Administration will release the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the Commercial Health Insurance Innovative Drug Catalog [1] Group 1 - A total of 114 drugs were successfully included in the basic medical insurance catalog, which includes 50 Class 1 innovative drugs, achieving a success rate of 88%, the highest negotiation success rate in nearly seven years [1] - The first version of the commercial insurance catalog includes 19 products, among which 5 are CAR-T products [1] - Continuous policy support and encouragement from the government for innovative drugs, along with the parallel operation of basic medical insurance and commercial insurance, is expected to diversify payment methods and gradually enhance the returns for innovative drug companies [1]

Core Viewpoint - The article discusses the recent developments in the investment banking sector, highlighting key trends and potential opportunities for investors [1] Group 1: Industry Trends - The investment banking industry is experiencing a shift towards digital transformation, with firms increasingly adopting technology to enhance efficiency and client service [1] - There is a growing emphasis on sustainable finance, as more investment banks are integrating environmental, social, and governance (ESG) criteria into their decision-making processes [1] Group 2: Company Insights - Major investment banks are reporting strong earnings, driven by robust trading activities and advisory services, indicating a positive outlook for the sector [1] - Companies are focusing on expanding their market presence through strategic mergers and acquisitions, which could lead to increased market share and revenue growth [1]

今年以来，医药生物板块整体保持稳健运行，防御性与增长韧性凸显，板块内部细分领域的分化特征愈 发明显。日前，财信证券研究发展中心医药生物行业首席分析师吴号表示，在政策支持升级与行业转型 深化的双重推动下，医药生物行业已全面迈入创新驱动的高质量发展阶段，"鼓励创新+成本控制"的政 策导向进一步塑造行业格局。随着行业基本面逐步修复，创新药、CXO、消费医疗三大投资主线的性 价比持续凸显，而AI等新技术与产业的深度融合，更开辟了全新增长空间，行业长期发展逻辑清晰， 投资价值逐步释放。（中证网） ...

【今日速览】 ①数字孪生+元宇宙+智慧社区+军工信息化！公司已在公安、气象、交通、健康与社区服务等垂直领 域，研发与具体业务场景深度结合的专用智能体；②人形机器人+eVTOL+大飞机+通用航空+商业航 天！公司获得人形机器人加工件定点采购协议；③燃料电池+氢能+航空航天+可控核聚变+量子计 算！公司为"华龙一号"核电站提供成套混凝土冷却系统。 【臻选回顾】 公告臻选12月1日提示《恒逸石化：控股股东及其一致行动人拟15亿元-25亿元增持公司股份》， 恒逸石化12月2日高开高走封死涨停直至收盘，12月3日再度上涨3%；公告臻选12月2日提示《稀 土永磁+钨钼+锂电+核聚变！公司光伏用细钨丝市场份额超80%》，厦门钨业12月3日逆市飘红， 12月5日、8日分别上涨1.77%、3.86%；公告臻选12月2日提示《主控芯片+高端封测+存储器 +AI，公司拟定增37亿元用于面向AI领域的高端存储器等项目》，江波龙12月8日大涨14.64%；12 月3日提示《多肽药+创新药+原料药+减肥药！公司产品通过药监局化妆品新原料备案》，圣诺生物 12月4日低开高走收涨3.55%；12月4日提示《显示驱动芯片+CMOS图像传感器+ ...

Core Insights - The recent adjustment to the national medical insurance directory emphasizes support for innovative drugs, with 114 new drugs added, 111 of which are newly approved within the last five years [3][10] - A new "Commercial Health Insurance Innovative Drug Directory" has been established, featuring 19 innovative drugs, primarily targeting high-cost treatments [10][12] Group 1: Innovative Drug Support - The adjustment to the basic medical insurance directory focuses on innovative drugs, with over 70% of the newly added drugs being domestically developed [3][8] - The inclusion of innovative drugs aims to fill clinical gaps, particularly in cancer treatments, such as breast and lung cancer [3][10] - The success rate of negotiations for innovative drugs has exceeded 90%, indicating a consensus on supporting true innovation [10] Group 2: Commercial Health Insurance Directory - The newly established commercial health insurance directory provides a payment pathway for high-cost innovative drugs, which are often not covered by basic insurance [12][18] - The directory includes a significant number of cancer treatments, including CAR-T therapies, which can cost around 1 million yuan per dose [12][14] - The dual directory system (basic insurance and commercial insurance) aims to reduce patient financial burdens and promote pharmaceutical innovation [18]

Core Viewpoint - Zhejiang Apac Pharmaceutical Co., Ltd. has made significant progress in the transfer of control, with the Shenzhen Stock Exchange confirming the share transfer agreement, indicating a successful transition of control to Xinghao Holdings and its actual controller, Mr. Qiu Zhongxun [1][2] Group 1: Control Transfer Details - The share transfer involves a 14.61% stake at a price of 8.26 yuan per share, totaling 900 million yuan, marking a significant change in the company's control [1] - The new actual controller, Mr. Qiu Zhongxun, has over 20 years of experience in the pharmaceutical industry and is the chairman of Yaodou Technology, a leading digital pharmaceutical platform [2] Group 2: Financial and Strategic Implications - The control transfer includes a plan for a private placement of up to 700 million yuan, aimed at funding new drug research and development projects [2] - The confidence shown by the new controller through the private placement is expected to ensure the long-term stability and sustainable development of the company [2] Group 3: Future Development and Innovation - Apac Pharmaceutical is committed to transforming into an innovative drug company, focusing on a combination of generic and innovative drug development [4] - The company has 114 approved drug formulations, with 19 products having passed consistency evaluations, and is expected to benefit from the national drug centralized procurement [4][5] - The collaboration with Yaodou Technology is anticipated to enhance the commercialization of innovative products, improving the efficiency of research outcomes and providing a competitive edge in the market [5]

2025年国家医保药品目录成功新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。19种药品纳入首版商保创新药目录。 2025年国家医保药品目录纳入了一些弥补基本医保保障空白的药品，如三阴乳腺癌、胰腺癌、肺癌等重大疾病用药；朗格汉斯细胞组织细胞增生症、螯 合剂不耐受的地中海贫血症等罕见病用药；糖尿病、高胆固醇血症、自身免疫性疾病等慢性病用药。 纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病等罕见病治疗药品，还有阿尔茨海默病治疗药品等。 此次调整后，国家医保药品目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性病、精神疾病、罕见病、儿童用药等重点领域的 保障水平得到明显提升。 （来源：药研网） 12月7日，2025年创新药高质量发展大会在广州召开。与此同时，国家医保局发布了《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健 康保险创新药品目录》。明确新版药品目录自2026年1月1日起实施。 | 名称: | 国家医保局 人力资源社会保障部关于印发《国家基本医疗保险、生育保险和工伤保险药品目录》以 ...

Core Insights - The new National Medical Insurance Directory has added 114 new drugs, surpassing last year's addition of 91, with 50 being first-class innovative drugs, achieving an overall success rate of 88%, an improvement from 76% in 2024 [1][2] Group 1: New Drug Additions - The total number of drugs in the directory has increased to 3,253, significantly enhancing coverage for key areas such as oncology and chronic diseases [2] - The directory includes 38 global innovative drugs and 50 first-class innovative drugs, marking a historical high for new additions [2] - Notable inclusions are the first globally approved red blood cell maturation agent, Rotecip, for treating lower-risk myelodysplastic syndromes, and the first domestically developed IL-4Rα antibody drug, Kangyueda, for multiple indications [3][4] Group 2: Oncology Innovations - Several innovative oncology drugs have been added, including Tagolizumab, the first PD-L1 monoclonal antibody approved for nasopharyngeal carcinoma, and non-covalent BTK inhibitor, Jebatib, for relapsed mantle cell lymphoma [4][5][6] - ADCs (antibody-drug conjugates) have gained attention, with new entries like Lukanasatuzumab and Ruikangquzuzumab, targeting advanced breast cancer and non-small cell lung cancer [7][8] Group 3: Chronic Disease Treatments - The directory has included innovative drugs for chronic diseases, such as Novartis' PCSK9 mRNA interference drug for cholesterol management, addressing patients who cannot reach LDL-C targets [14] - AstraZeneca's biologic drug Benralizumab for severe eosinophilic asthma has also been added, providing targeted treatment options for patients [15][16] Group 4: Influenza Treatments - The new directory has incorporated two domestic antiviral drugs for influenza, Masurashave and Angladiv, which have shown promising clinical results in reducing symptoms and viral load [17]